Literature DB >> 21193998

Serum biomarkers for improved diagnostic of pancreatic cancer: a current overview.

S Bünger1, T Laubert, U J Roblick, J K Habermann.   

Abstract

PURPOSE: Complete resection constitutes the only curative approach in pancreatic cancer but is possible only in a minority of patients due to advanced stages upon diagnosis. Consequently, early detection is crucial for curative treatment. Clinical routine still lacks efficient, non-invasive screening assays, and 80-90% of pancreatic carcinomas are detected at unresectable stages. A wide range of serum proteins have been in the focus of intensive search for biomarkers specific for pancreatic cancer. This article will give an overview on serum biomarkers with screening potential for pancreatic malignancy. DESIGN AND METHODS: PUBMED database was searched for articles, and 43 manuscripts were selected that provided data regarding biomarkers used, type of assay, study population, sample cohort quality and diagnostic performance.
RESULTS: Superior values for diagnostic performance were shown for MIC-1, PAM4, OPN, HSP27, TPS, TSGF, and CAM17.1 as individual markers. Panels of biomarkers comprised CA 19-9, MCSF, CEA, SAA, Haptoglobin, TSGF, CA 242, and HSP27. Individually or in concerted form, sensitivity and specificity ranged from 77 to 100% and 84-100%, respectively.
CONCLUSIONS: While the above named markers show high screening potential for pancreatic cancer, standardized validation studies using multiplex assays are required to pave the way for clinical routine application.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21193998     DOI: 10.1007/s00432-010-0965-x

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  54 in total

1.  Minimum information about a microarray experiment (MIAME)-toward standards for microarray data.

Authors:  A Brazma; P Hingamp; J Quackenbush; G Sherlock; P Spellman; C Stoeckert; J Aach; W Ansorge; C A Ball; H C Causton; T Gaasterland; P Glenisson; F C Holstege; I F Kim; V Markowitz; J C Matese; H Parkinson; A Robinson; U Sarkans; S Schulze-Kremer; J Stewart; R Taylor; J Vilo; M Vingron
Journal:  Nat Genet       Date:  2001-12       Impact factor: 38.330

2.  Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer.

Authors:  Asma Sultana; Catrin Tudur Smith; David Cunningham; Naureen Starling; John P Neoptolemos; Paula Ghaneh
Journal:  J Clin Oncol       Date:  2007-06-20       Impact factor: 44.544

Review 3.  The minimum information about a proteomics experiment (MIAPE).

Authors:  Chris F Taylor; Norman W Paton; Kathryn S Lilley; Pierre-Alain Binz; Randall K Julian; Andrew R Jones; Weimin Zhu; Rolf Apweiler; Ruedi Aebersold; Eric W Deutsch; Michael J Dunn; Albert J R Heck; Alexander Leitner; Marcus Macht; Matthias Mann; Lennart Martens; Thomas A Neubert; Scott D Patterson; Peipei Ping; Sean L Seymour; Puneet Souda; Akira Tsugita; Joel Vandekerckhove; Thomas M Vondriska; Julian P Whitelegge; Marc R Wilkins; Ioannnis Xenarios; John R Yates; Henning Hermjakob
Journal:  Nat Biotechnol       Date:  2007-08       Impact factor: 54.908

4.  [Present status of and prospects for basic research on pancreatic cancer].

Authors:  Yu-pei Zhao; Tai-ping Zhang
Journal:  Zhonghua Yi Xue Za Zhi       Date:  2008-07-22

5.  Detection of early-stage pancreatic adenocarcinoma.

Authors:  David V Gold; Michael Goggins; David E Modrak; Guy Newsome; Mengling Liu; Chanjuan Shi; Ralph H Hruban; David M Goldenberg
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-09-01       Impact factor: 4.254

Review 6.  Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer.

Authors:  K S Goonetilleke; A K Siriwardena
Journal:  Eur J Surg Oncol       Date:  2006-11-09       Impact factor: 4.424

7.  CEACAM1, a novel serum biomarker for pancreatic cancer.

Authors:  Diane M Simeone; Baoan Ji; Mousumi Banerjee; Thiruvengadam Arumugam; Dawei Li; Michelle A Anderson; Ann Marie Bamberger; Joel Greenson; Randal E Brand; Vijaya Ramachandran; Craig D Logsdon
Journal:  Pancreas       Date:  2007-05       Impact factor: 3.327

Review 8.  Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Standards for Reporting of Diagnostic Accuracy.

Authors:  Patrick M Bossuyt; Johannes B Reitsma; David E Bruns; Constantine A Gatsonis; Paul P Glasziou; Les M Irwig; Jeroen G Lijmer; David Moher; Drummond Rennie; Henrica C W de Vet
Journal:  Clin Chem       Date:  2003-01       Impact factor: 8.327

9.  A prospective study of serum tumour markers carcinoembryonic antigen, carbohydrate antigens 50 and 242, tissue polypeptide antigen and tissue polypeptide specific antigen in the diagnosis of pancreatic cancer with special reference to multivariate diagnostic score.

Authors:  P A Pasanen; M Eskelinen; K Partanen; P Pikkarainen; I Penttilä; E Alhava
Journal:  Br J Cancer       Date:  1994-03       Impact factor: 7.640

10.  REporting recommendations for tumour MARKer prognostic studies (REMARK).

Authors:  L M McShane; D G Altman; W Sauerbrei; S E Taube; M Gion; G M Clark
Journal:  Br J Cancer       Date:  2005-08-22       Impact factor: 7.640

View more
  49 in total

Review 1.  Prognostic factors related with survival in patients with pancreatic adenocarcinoma.

Authors:  Ahmet Bilici
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

Review 2.  SIBLINGs and SPARC families: their emerging roles in pancreatic cancer.

Authors:  Ferda Kaleağasıoğlu; Martin R Berger
Journal:  World J Gastroenterol       Date:  2014-10-28       Impact factor: 5.742

3.  Role of IL-6 in the resolution of pancreatitis in obese mice.

Authors:  Maria Pini; Davina H Rhodes; Karla J Castellanos; Andrew R Hall; Robert J Cabay; Rohini Chennuri; Eileen F Grady; Giamila Fantuzzi
Journal:  J Leukoc Biol       Date:  2012-03-16       Impact factor: 4.962

Review 4.  Advances in biomarker research for pancreatic cancer.

Authors:  Kruttika Bhat; Fengfei Wang; Qingyong Ma; Qinyu Li; Sanku Mallik; Tze-Chen Hsieh; Erxi Wu
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

5.  CD14-expressing cancer cells establish the inflammatory and proliferative tumor microenvironment in bladder cancer.

Authors:  Ming T Cheah; James Y Chen; Debashis Sahoo; Humberto Contreras-Trujillo; Anne K Volkmer; Ferenc A Scheeren; Jens-Peter Volkmer; Irving L Weissman
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-30       Impact factor: 11.205

Review 6.  Imaging in pancreatic disease.

Authors:  Julien Dimastromatteo; Teresa Brentnall; Kimberly A Kelly
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-11-09       Impact factor: 46.802

7.  Plasma protein profiling in a stage defined pancreatic cancer cohort - Implications for early diagnosis.

Authors:  Anna Sandström Gerdtsson; Christer Wingren; Helena Persson; Payam Delfani; Malin Nordström; He Ren; Xin Wen; Ulrika Ringdahl; Carl A K Borrebaeck; Jihui Hao
Journal:  Mol Oncol       Date:  2016-07-12       Impact factor: 6.603

8.  CA19-9 and CA242 as tumor markers for the diagnosis of pancreatic cancer: a meta-analysis.

Authors:  Ji-Cong Gui; Wei-Li Yan; Xing-Dang Liu
Journal:  Clin Exp Med       Date:  2013-03-03       Impact factor: 3.984

9.  Prognostic implication of serum hepatocyte growth factor in stage II/III breast cancer patients who received neoadjuvant chemotherapy.

Authors:  Hyori Kim; Jeonghwan Youk; Yaewon Yang; Tae-Yong Kim; Ahrum Min; Hye-Seon Ham; Seongcheol Cho; Kyung-Hun Lee; Bhumsuk Keam; Sae-Won Han; Do-Youn Oh; Han Suk Ryu; Wonshik Han; In Ae Park; Tae-You Kim; Dong-Young Noh; Seock-Ah Im
Journal:  J Cancer Res Clin Oncol       Date:  2015-11-18       Impact factor: 4.553

Review 10.  Clinical approach to the patient with a solid pancreatic mass.

Authors:  Reinhold Függer; Odo Gangl; Uwe Fröschl
Journal:  Wien Med Wochenschr       Date:  2014-02-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.